Seres Therapeutics (NASDAQ:MCRB) Share Price Crosses Below 50 Day Moving Average – Time to Sell?

Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) crossed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $8.31 and traded as low as $7.53. Seres Therapeutics shares last traded at $7.63, with a volume of 25,619 shares.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on MCRB shares. Weiss Ratings downgraded shares of Seres Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, May 18th. Wall Street Zen downgraded shares of Seres Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Seres Therapeutics in a report on Friday, March 13th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $22.00.

Seres Therapeutics Stock Performance

The company has a market capitalization of $73.86 million, a price-to-earnings ratio of -1.48 and a beta of 0.12. The stock’s fifty day simple moving average is $8.31 and its two-hundred day simple moving average is $12.20.

Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($2.08) EPS for the quarter, missing analysts’ consensus estimates of ($1.88) by ($0.20). The business had revenue of $0.36 million for the quarter, compared to the consensus estimate of $0.36 million.

Institutional Trading of Seres Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Invesco Ltd. lifted its stake in Seres Therapeutics by 37.5% during the fourth quarter. Invesco Ltd. now owns 14,360 shares of the biotechnology company’s stock valued at $214,000 after buying an additional 3,918 shares in the last quarter. 683 Capital Management LLC purchased a new stake in Seres Therapeutics during the fourth quarter valued at about $778,000. ExodusPoint Capital Management LP purchased a new stake in Seres Therapeutics during the fourth quarter valued at about $190,000. OMERS ADMINISTRATION Corp purchased a new stake in Seres Therapeutics during the fourth quarter valued at about $214,000. Finally, Barclays PLC lifted its stake in Seres Therapeutics by 427.8% during the fourth quarter. Barclays PLC now owns 7,432 shares of the biotechnology company’s stock valued at $111,000 after buying an additional 6,024 shares in the last quarter. 59.34% of the stock is owned by hedge funds and other institutional investors.

About Seres Therapeutics

Seres Therapeutics is a clinical?stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.